CRBAF
CRBAF operates in various business sectors.
CRBAF (CRBAF) - Net Assets
Latest net assets as of June 2024: $-6.81 Million USD
Based on the latest financial reports, CRBAF (CRBAF) has net assets worth $-6.81 Million USD as of June 2024.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets ($134.72K) and total liabilities ($6.94 Million). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | $-6.81 Million |
| % of Total Assets | -5052.58% |
| Annual Growth Rate | N/A |
| 5-Year Change | N/A |
| 10-Year Change | N/A |
| Growth Volatility | N/A |
CRBAF - Net Assets Trend (2022–2023)
This chart illustrates how CRBAF's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for CRBAF (2022–2023)
The table below shows the annual net assets of CRBAF from 2022 to 2023.
| Year | Net Assets | Change |
|---|---|---|
| 2023-12-31 | $-5.69 Million | -549.13% |
| 2022-12-31 | $1.27 Million | -- |
Equity Component Analysis
This analysis shows how different components contribute to CRBAF's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have decreased by 979790900.0% over the analyzed period, potentially due to dividend distributions or operating losses.
Current Equity Component Breakdown (December 2023)
| Component | Amount | Percentage |
|---|---|---|
| Other Components | $16.45 Million | % |
| Total Equity | $-5.69 Million | 100.00% |
CRBAF Competitors by Market Cap
The table below lists competitors of CRBAF ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Celadon Pharmaceuticals PLC
LSE:CEL
|
$1.12K |
|
Asiri Hospital Holdings PLC
CM:ASIRN0000
|
$1.12K |
|
BXNS
PINK:BXNS
|
$1.12K |
|
SUNAC CHINA HLDGS (SCNR.SG)
STU:SCNR
|
$1.12K |
|
Telemedpl
WAR:TMP
|
$1.12K |
|
Uniroyal Global Engineered Products Inc
PINK:UNIR
|
$1.12K |
|
Cuentas Inc
PINK:CUEN
|
$1.12K |
|
Hemas Holdings PLC
CM:HHLN0000
|
$1.12K |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in CRBAF's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2022 to 2023, total equity changed from 1,265,921 to -5,685,631, a change of -6,951,552 (-549.1%).
- Net loss of 9,797,909 reduced equity.
- New share issuances of 1,000,000 increased equity.
- Other factors increased equity by 1,846,357.
Equity Change Factors (2022 to 2023)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | $-9.80 Million | -172.33% |
| Share Issuances | $1.00 Million | +17.59% |
| Other Changes | $1.85 Million | +32.47% |
| Total Change | $- | -549.13% |
Book Value vs Market Value Analysis
This analysis compares CRBAF's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2022-12-31 | $0.02 | $0.11 | x |
| 2023-12-31 | $-0.07 | $0.11 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently CRBAF utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 0.00%
- The company may be facing challenges in efficiently utilizing shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 0.00%
- • Asset Turnover: 0.00x
- • Equity Multiplier: 0.00x
- Recent ROE (0.00%) is above the historical average (-189.21%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2022 | -378.42% | 0.00% | 0.00x | 4.52x | $-4.92 Million |
| 2023 | 0.00% | 0.00% | 0.00x | 0.00x | $-9.23 Million |
Industry Comparison
This section compares CRBAF's net assets metrics with peer companies in the same industry.
No peer company data available for comparison.